A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours

A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours

(2017) Maja de Jonge et al.   EUROPEAN JOURNAL OF CANCER

A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma

(2016) M.H. Langenberg et al.   EUROPEAN JOURNAL OF CANCER

Dose- and regimen-finding phase I study of NVP-HDM201 in patients (pts) with TP53 wild-type (wt) advanced tumors

(2016) D. Hyman et al.   EUROPEAN JOURNAL OF CANCER

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma

(2016) Joonil Jung et al.   Nature Communications

P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis

(2016) Emna Mahfoudhi et al.   Oncotarget

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

(2015) T Macarulla et al.   BRITISH JOURNAL OF CANCER

303 A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumors

(2015) V. De Weger et al.   EUROPEAN JOURNAL OF CANCER

Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies

(2015) F Ravandi et al.   Blood Cancer Journal

Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis

(2013) Camelia Iancu-Rubin et al.   EXPERIMENTAL HEMATOLOGY

604 Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial

(2012) A. Awada et al.   EUROPEAN JOURNAL OF CANCER

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

(2012) Isabelle Ray-Coquard et al.   LANCET ONCOLOGY

Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors

(2009) Austin Duffy et al.   Targeted Oncology

TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use

(2009) M. Olivier et al.   Cold Spring Harbor Perspectives in Biology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER